Pathway for Softgel vs Tablet Comparison [Design Issues]

posted by Obinoscopy  – USA, 2018-05-15 19:04 (1297 d 07:54 ago) – Posting: # 18764
Views: 2,169

Dear bebac_fan,

» I think this would need to go through a NDA/505(b)(2) pathway rather than an ANDA.
»

I share the same view with you on this.

However I have a case where a BE study was conducted comparing Metronidazole tablet (Reference) with Metronidazole soft gel (test). Both were IR. Is this acceptable?

Regards,

Scopy

Complete thread:

Activity
 Admin contact
21,785 posts in 4,556 threads, 1,547 registered users;
online 14 (1 registered, 13 guests [including 8 identified bots]).
Forum time: Friday 01:58 CET (Europe/Vienna)

A drug is that substance which, when injected into a rat,
will produce a scientific report.    Anonymous

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5